Genetic variants in ERAP1 and ERAP2 associated with immune ‐mediated diseases influence protein expression and isoform profile

ConclusionsIn accordance with studies demonstrating that polymorphisms that increase aminopeptidase activity predispose to immune disease, the elevated risk also attributed to increased expression of ERAP1 and ERAP2 supports the therapeutic notion of aminopeptidase inhibition to treat AS and other ERAP associated conditions.This article is protected by copyright. All rights reserved.

Source: Arthritis and Rheumatism - November 6, 2017 Category: Rheumatology Authors: Aimee L. Hanson, Thomas Cuddihy, Katelin Haynes, Dorothy Loo, Craig J. Morton, Udo Oppermann, Paul Leo, Gethin P. Thomas, Kim ‐Anh Lê Cao, Tony J. Kenna, Matthew A. Brown Tags: Full Length Source Type: research